Competitor Analysis: Respiratory Syncytial Virus (RSV) Antibodies, Vaccines & Antivirals 2017 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Competitor Analysis: Respiratory Syncytial Virus (RSV) Antibodies, Vaccines & Antivirals 2017" report to their offering.

This Competitive Intelligence Report about RSV Antibodies, Vaccines & Antivirals provides a competitor evaluation in the field of prophylactic vaccines and therapeutic antibodies, small molecules, protein and peptide therapeutics against infection caused by respiratory syncytial virus (RSV) as of March 2017.

Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infections among young children in the United States and worldwide. Most infants are infected before the age of one, and virtually everyone gets an RSV infection by the age of two. A prophylactic vaccine is not available and specific treatment is limited to the monoclonal antibody Synagis (palivizumb), a candidate for biosimilar conversion in the near future.

RSV infection in the pediatric and adult populations account for more than 300,000 hospitalizations per year in the U.S. In the developing world, RSV is responsible for 30 million cases of acute respiratory tract infection and 200,000 deaths per year. As a result, there is a significant need for novel therapeutics to prevent RSV infection.

The report includes a compilation of currently active projects in development of vaccines, antibodies, small molecules, peptides and proteins targeting respiratory syncytial virus for prophylaxis and treatment of RSV infections. In addition, the report lists company-specific R&D pipelines of RSV Antibodies, Vaccines & Antivirals.

Competitor projects are listed in a tabular format providing information on:

- Drug Codes

- Target/Mechanism of Action

- Class of Compound

- Company

- Product Category

- Indication

- R&D Stage

- Additional comments with a hyperlink leading to the source of information.

Key Topics Covered:

1. RSV Antibodies:

- Palivizumab Biosuperiors

- Palivizumab Biosimilars

2. RSV Antivirals:

- Small Molecule Therapeuticss

- Other RSV Therapeutics

3. RSV Vaccines:

- Live-Attenuated & Whole-Inactivated RSV Vaccines

- Virus-Like Particle (VLP) RSV Vaccines

- Subunit RSV Vaccines

- DNA-/RNA-Based RSV Vaccines

For more information about this report visit https://www.researchandmarkets.com/research/4v7n77/competitor

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Immune Disorders Drugs, Infectious Diseases Drugs, Vaccines

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Immune Disorders Drugs, Infectious Diseases Drugs, Vaccines